<DOC>
	<DOCNO>NCT00962741</DOCNO>
	<brief_summary>This study evaluate effect etanercept clinical benefit , safety , physical functioning ( ability function daily life ) child adolescent subject 3 subtypes childhood arthritis .</brief_summary>
	<brief_title>Study Evaluating Etanercept 3 Subtypes Childhood Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Male female subject diagnosis per International League Associations Rheumatology ( ILAR ) criterion extend oligoarticular juvenile idiopathic arthritis ( JIA ) age 2 17 year ; enthesitisrelated arthritis ( ERA ) age 12 17 year ; psoriatic arthritis ( PsA ) age 12 17 year . &gt; = 2 active joint follow relevant JIA subtype : extend oligoarticular JIA PsA history intolerance unsatisfactory response disease modify antirheumatic drug ( DMARD ) ; ERA history intolerance unsatisfactory response nonsteroidal antiinflammatory drug ( NSAID ) DMARD . Systemic JIA , persistent oligoarticular JIA , polyarticular JIA , undifferentiated arthritis per ILAR criterion . Other rheumatic disease . Active uveitis within 6 month baseline visit . Any significant health problem .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>